Product/Composition:- | Ivabradine tablet |
---|---|
Strength:- | 5 mg, 7.5 mg, and 9 mg |
Form:- | Tablet |
Reference Brands:- | Corlanor(US), Procoralan(EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Ivabradine selectively inhibits funny current (If) channels in the sinoatrial node, lowering heart rate without affecting blood pressure or ventricular contractility. It reduces angina attacks, improves exercise tolerance, and decreases hospitalization risk in chronic heart failure. Benefits include better heart rate control, symptom relief, and improved quality of life.
Ivabradine tablets, marketed as Corlanor (US) and Procoralan (EU), are approved for chronic stable angina and heart failure management. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial and quality information, while the EMA ensures compliance with safety and manufacturing standards across European regions. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring regional regulatory adherence supports timely approval, safe use, and worldwide availability of ivabradine tablets, helping improve heart rate management and reduce cardiovascular events globally.